tetradecanoylphorbol acetate has been researched along with sotrastaurin in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Budde, K; Kramer, S; Ladhoff, J; Lorkowski, C; Mashreghi, MF; Matz, M; Neumayer, HH; Weber, U | 1 |
Andritsos, L; Awan, FT; Blachly, JS; Byrd, JC; Cannon, M; Chen, CS; El-Gamal, D; Jones, J; LaFollette, TD; Lapalombella, R; Lehman, A; Maddocks, K; Williams, E; Williams, K; Woyach, JA; Wu, CH; Zhang, X; Zhong, Y | 1 |
2 other study(ies) available for tetradecanoylphorbol acetate and sotrastaurin
Article | Year |
---|---|
Effects of the new immunosuppressive agent AEB071 on human immune cells.
Topics: CD4-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Cytokines; Dendritic Cells; Humans; Immunosuppressive Agents; Ionomycin; K562 Cells; Killer Cells, Natural; Leukocytes, Mononuclear; Protein Kinase C; Pyrroles; Quinazolines; Tetradecanoylphorbol Acetate | 2010 |
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.
Topics: Apoptosis; beta Catenin; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase C beta; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Antigen, B-Cell; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Tumor Microenvironment; Wnt Signaling Pathway | 2014 |